Source: Eur Respir Rev 2015; 24: 46-51
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Teschler Helmut. Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 2015; 24: 46-51

Member's Comments

No comment yet.

Related content which might interest you: Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017 Year: 2017 Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases Year: 2017 Phase I safety investigation of an aerosolized, recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 228s Year: 2004 A case report of alpha 1-antitrypsin deficiency in a six-month infant Source: Eur Respir J 2004; 24: Suppl. 48, 228s Year: 2004 Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Effects of biweekly Alpha1 antitrypsin replacement therapy: a case series Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020 Alpha 1 - antitrypsin deficiency: diagnosis and treatment Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment Year: 2021 Diagnosing alpha 1-antitrypsin deficiency: how to improve the current algorithm Source: Eur Respir Rev 2015; 24: 52-57 Year: 2015 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019 Year: 2019 COVID-19 infection in Severe Alpha 1-antitrypsin deficiency: looking for a rationale Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough Source: Eur Respir J 2016; 47: 35-38 Year: 2016 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits Source: Eur Respir J, 50 (3) 1700198; 10.1183/13993003.00198-2017 Year: 2017 Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Targeted screening programmes in COPD: how to identify individuals with alpha 1-antitrypsin deficiency Source: Eur Respir Rev 2015; 24: 40-45 Year: 2015 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Does smoking impair the quality of life of 34 year olds with alpha-1 antitrypsin deficiency? Source: Annual Congress 2011 - Smoking-related disorders and smoking prevention Year: 2011